0001839882-23-028167.txt : 20231026 0001839882-23-028167.hdr.sgml : 20231026 20231026071742 ACCESSION NUMBER: 0001839882-23-028167 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20231026 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231026 DATE AS OF CHANGE: 20231026 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Tonix Pharmaceuticals Holding Corp. CENTRAL INDEX KEY: 0001430306 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 261434750 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36019 FILM NUMBER: 231347490 BUSINESS ADDRESS: STREET 1: 26 MAIN STREET, SUITE 101 CITY: CHATHAM STATE: NJ ZIP: 07928 BUSINESS PHONE: 212-980-9155 MAIL ADDRESS: STREET 1: 26 MAIN STREET, SUITE 101 CITY: CHATHAM STATE: NJ ZIP: 07928 FORMER COMPANY: FORMER CONFORMED NAME: TAMANDARE EXPLORATIONS INC. DATE OF NAME CHANGE: 20080320 8-K 1 tnxp-8k_102623.htm CURRENT REPORT
0001430306 false 0001430306 2023-10-26 2023-10-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (date of earliest event reported): October 26, 2023

 

TONIX PHARMACEUTICALS HOLDING CORP.  

(Exact name of registrant as specified in its charter)

 

Nevada 001-36019 26-1434750

(State or Other Jurisdiction  

of Incorporation)  

(Commission  

File Number) 

(IRS Employer  

Identification No.)  

 

26 Main Street, Chatham, New Jersey 07928

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (862) 904-8182

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock TNXP The NASDAQ Capital Market

   

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). 

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

 

 

 

 

 

  Item 7.01 Regulation FD Disclosure.

 

On October 26, 2023, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced the completion of the clinical phase of the Phase 2 proof-of-concept, double-blind, randomized, placebo-controlled PREVENTION study of the Company’s TNX-1900 (intranasal potentiated oxytocin) product candidate as a potential treatment for the prevention of migraine headaches in chronic migraineurs. A copy of the press release which discusses this matter is furnished hereto as Exhibit 99.01, and incorporated herein by reference.

 

The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.01 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the United States Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the United States Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 8.01.Other Events.

 

On October 26, 2023, the Company announced the completion of the Phase 2 PREVENTION study of TNX-1900 as a potential treatment for the prevention of migraine headaches in chronic migraineurs. A total of 88 patients were enrolled in this multi-site study in the U.S. Topline results are expected in early December 2023.

 

Forward- Looking Statements 

 

This Current Report on Form 8-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

 

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the SEC. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. 

 

  Item 9.01 Financial Statements and Exhibits.

 

(d)  

Exhibit

No.

   Description.
   

99.01

104

  

Press release of the Company, dated October 26, 2023

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURE

 

Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  TONIX PHARMACEUTICALS HOLDING CORP.
   
Date: October 26, 2023 By: /s/ Bradley Saenger  
  Bradley Saenger
  Chief Financial Officer

 

 

 

 EX-99.01 2 ex99-01.htm PRESS RELEASE

 

 

 Tonix Pharmaceuticals 8-K

Exhibit 99.01

 

Tonix Pharmaceuticals Completes Clinical Stage of Phase 2 PREVENTION Study of TNX-1900 for the Prevention of Migraine Headaches in Chronic Migraineurs

 

Topline results expected early December 2023

 

Novel formulation of intranasal oxytocin contains magnesium (Mg2+), shown to potentiate the analgesic effects of oxytocin on the oxytocin receptor in animal models

 

TNX-1900 blocks release of CGRP, a key peptide in the pathogenesis of migraine, from trigeminal ganglia neurons while limiting systemic exposure

 

CHATHAM, N.J., October 26, 2023 – Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced the completion of the clinical phase of the Phase 2 proof-of-concept, double-blind, randomized, placebo-controlled PREVENTION1 study of TNX-19002 (intranasal potentiated oxytocin) as a potential treatment for the prevention of migraine headaches in chronic migraineurs. A total of 88 patients were enrolled in this multi-site study in the U.S. Topline results are expected in early December 2023.

 

TNX-1900 is a proprietary formulation of oxytocin that contains magnesium, which Tonix has shown in animal models potentiates the action of oxytocin at oxytocin receptors and potentially improves the consistency of treatment by reducing paradoxical high-dose inhibition. Its unique, multimodal mechanism of action includes an ability to inhibit the release of the trigeminal neuropeptide calcitonin gene-related peptide (CGRP) in blood vessels within the brain, its lining and the brainstem, and to suppress signaling in pain neurons. Tonix believes that by engaging and activating oxytocin receptors in the trigeminal ganglia, TNX-1900 has the potential to help those suffering from chronic migraine.

 

“TNX-1900 is being developed as a novel, non-CGRP antagonist approach to treatment for chronic migraineurs,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “There are an estimated four million individuals in the U.S. suffering from this debilitating condition, and despite several classes of migraine preventives available, there remains an unmet need for novel approaches.”

 

“With the last patient now treated, we look forward to analysis of the results of this proof-of-concept study, which will help to inform our plans as we discuss next steps with the U.S. Food and Drug Administration (FDA),” said Gregory Sullivan, M.D., Chief Medical Officer of Tonix Pharmaceuticals. “We would like to thank the participants, their families, and all the investigators and researchers who have been an important part of this journey so far.”

 

1Clinical Trials.gov I.D. NCT05679908

2TNX-1900 is an investigational new drug and is not approved for any indication.

 

About the Phase 2 PREVENTION Study

 

The Phase 2 PREVENTION study is a double-blind, randomized, multicenter, placebo-controlled study to evaluate the efficacy and safety of TNX-1900 taken prophylactically on a daily basis to prevent chronic migraine. There are three arms: two treatment regimens of TNX-1900 and one placebo in a 1:1:1 ratio in a total of 88 participants across approximately 26 U.S. sites. After a four-week Run-In phase to confirm chronic migraine criteria are met, there are 12-weeks of a double-blind Treatment phase with study drug, followed by a 2-week safety Follow-Up phase. The primary efficacy endpoint is mean change in the number of migraine headache days between the 28-day Run-In phase and the last 28-days of thTreatment phase. Key secondary efficacy endpoints include proportion of patients experiencing a ≥ 50% reduction in the number of migraine headache days, mean change in the number of days using migraine abortive medications, and mean change in a migraine-specific quality of life measure.

 

For more information, see ClinicalTrials.gov Identifier: NCT05679908.

 

 

 

  

About Migraine

 

Migraine is a neurological condition that typically manifests in a throbbing moderate to severe headache which lasts at least four hours, often on one side of the head and aggravated by routine physical activity. It can also be accompanied by nausea, vomiting, visual disturbances, and sensitivity to bright light and loud noises1. Epidemiological studies indicate that globally, approximately 1.2 billion individuals suffer from migraines annually.2 In the U.S., approximately 39 million Americans suffer from migraines and among these individuals, approximately four million experience chronic migraines (15 or more headache days per month, at least eight of which are migraines).2 The current FDA approved drugs for migraine prevention in chronic migraine include Botox® (onabotulinumtoxinA), and the anti-CGRP/CGRP-R monoclonal antibodies Aimovig® (erenumab), Vyepti® (eptinezumab), Ajovy® (fremanezumab) and Emgality® (galcanezumab).

 

1The International Classification of Headache Disorders, 3rd Edition. Cephalalgia. 2018. 38(1):1-211.

 

2Burch et al., Migraine: Epidemiology, Burden, and Comorbidity. Neurol Clin. 2019. 631–649.

 

About TNX-1900

 

TNX-1900 (intranasal potentiated oxytocin) is a proprietary formulation of oxytocin in development as a candidate for prevention in chronic migraine and other conditions. In 2020, TNX-1900 was acquired from Trigemina, Inc. who had licensed the technology underlying the composition and method from Stanford University. TNX-1900 is a drug-device combination product, based on an intranasal actuator device that delivers oxytocin into the nasal cavity. Oxytocin is a naturally occurring human peptide hormone that also acts as a neurotransmitter in the brain. Oxytocin has no recognized addiction potential. It has been observed that low oxytocin levels in the body are associated with increases in migraine headache frequency, and that increased oxytocin levels are associated with fewer migraine headaches. Certain other chronic pain conditions are also associated with decreased oxytocin levels. Migraine attacks are caused, in part, by the activity of pain-sensing trigeminal neurons which, when activated, release of calcitonin gene-related peptide (CGRP) which binds to receptors on other nerve cells and starts a cascade of events that is believed to result in headache. Oxytocin, when delivered via the nasal route, concentrates in the trigeminal system1 resulting in binding of oxytocin to receptors on neurons in the trigeminal system, inhibiting the release of CGRP and transmission of pain signals returning from the site of CGRP release2. Blocking CGRP release is a distinct mechanism compared with CGRP antagonist and anti-CGRP antibody drugs, which block the binding of CGRP to its receptor. With TNX-1900, the addition of magnesium to the oxytocin formulation enhances oxytocin receptor binding3 as well as its inhibitory effects on trigeminal neurons and resultant craniofacial analgesic effects, as demonstrated in animal models4. Intranasal oxytocin has been shown to be well tolerated in several clinical trials in both adults and children5. Targeted nasal delivery results in low systemic exposure and lower risk of non-nervous system, off-target effects, which could potentially occur with systemic CGRP antagonists such as anti-CGRP antibodies6. For example, CGRP has roles in dilating blood vessels in response to ischemia, including in the heart. The Company believes nasally targeted delivery of oxytocin could translate into selective blockade of CGRP release from neurons in the trigeminal ganglion and not throughout the body, which could be a potential safety advantage over systemic CGRP inhibition. In addition, daily dosing is more rapidly reversible, in contrast to monthly or quarterly dosing, as is the case with anti-CGRP antibodies, giving physicians and their patients greater control. In addition to chronic migraine, TNX-1900 will be developed for treatment of episodic migraine, binge eating disorder, craniofacial pain conditions, and insulin resistance. Tonix also has a license with the University of Geneva to use TNX-1900 for the treatment of insulin resistance and related conditions.

 

 

 

 

1Yeomans DC, et al. Transl Psychiatry. 2021. 11(1):388.

 

2Tzabazis A, et al. Cephalalgia. 2016. 36(10):943-50.

 

3Antoni FA and Chadio SE. Biochem J. 1989. 257(2):611-4.

 

4Cai Q, et al., Psychiatry Clin Neurosci. 2018. 72(3):140-151.

 

5Yeomans, DC et al. 2017. US patent US2017368095.

 

6MaassenVanDenBrink A, et al. Trends Pharmacol Sci. 2016. 37(9):779-788.

 

Tonix Pharmaceuticals Holding Corp.*

 

Tonix is a biopharmaceutical company focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease and alleviate suffering. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg under a transition services agreement with Upsher-Smith Laboratories, LLC from whom the products were acquired on June 30, 2023. Zembrace SymTouch and Tosymra are each indicated for the treatment of acute migraine with or without aura in adults. Tonix’s development portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates. Tonix’s CNS development portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead development CNS candidate, TNX-102 SL (cyclobenzaprine HCl sublingual tablet), is in mid-Phase 3 development for the management of fibromyalgia, having completed enrollment of a potentially confirmatory Phase 3 study in the third quarter of 2023, with topline data expected in late December 2023. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Enrollment in a Phase 2 proof-of-concept study has been completed, and topline results were reported in the third quarter of 2023. TNX-601 ER (tianeptine hemioxalate extended-release tablets) is a once-daily oral formulation being developed as a treatment for major depressive disorder (MDD), that completed enrollment in a Phase 2 study in the third quarter of 2023, with topline results expected in early November of 2023. TNX-4300 (estianeptine) is a single isomer version of TNX-601, a small molecule oral therapeutic in preclinical development to treat MDD, Alzheimer’s disease and Parkinson’s disease. Relative to tianeptine, estianeptine lacks activity on the mu-opioid receptor while maintaining activity and the ability to activate PPAR-β/δ and neuroplasticity in tissue culture. TNX-1900 (intranasal potentiated oxytocin), is in development as a preventive treatment in chronic migraine, and the clinical phase of a Phase 2 proof-of-concept study is now completed with topline data expected in early December 2023. TNX-1900 is also being studied in binge eating disorder, pediatric obesity and social anxiety disorder by academic collaborators under investigator-initiated INDs. TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted Breakthrough Therapy designation by the FDA. A Phase 2 study of TNX-1300 is expected to be initiated in the fourth quarter of 2023. Tonix’s rare disease development portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome. TNX-2900 has been granted Orphan Drug designation by the FDA. Tonix’s immunology development portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 was initiated in the third quarter of 2023. Tonix’s infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800, in development as a vaccine to protect against COVID-19. The infectious disease development portfolio also includes TNX-3900 and TNX-4000, which are classes of broad-spectrum small molecule oral antivirals.

 

*Tonix’s product development candidates are investigational new drugs or biologics and have not been approved for any indication.

 

 

 

  

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. Intravail is a registered trademark of Aegis Therapeutics, LLC, a wholly owned subsidiary of Neurelis, Inc. All other marks are property of their respective owners.

 

This press release and further information about Tonix can be found at www.tonixpharma.com.

 

Forward Looking Statements

 

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the Securities and Exchange Commission (the “SEC”) on March 13, 2023, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

 

Investor Contact

 

Jessica Morris

Tonix Pharmaceuticals

investor.relations@tonixpharma.com

(862) 904-8182

 

Peter Vozzo

ICR Westwicke

peter.vozzo@westwicke.com

(443) 213-0505

 

 

 

 

Media Contact

 

Ben Shannon

ICR Westwicke

ben.shannon@westwicke.com

443-213-0495

 

 

 EX-101.SCH 3 tnxp-20231026.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 tnxp-20231026_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 tnxp-20231026_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Oct. 26, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 26, 2023
Entity File Number 001-36019
Entity Registrant Name TONIX PHARMACEUTICALS HOLDING CORP.
Entity Central Index Key 0001430306
Entity Tax Identification Number 26-1434750
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 26 Main Street
Entity Address, City or Town Chatham
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07928
City Area Code (862)
Local Phone Number 904-8182
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol TNXP
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 7 tnxp-8k_102623_htm.xml IDEA: XBRL DOCUMENT 0001430306 2023-10-26 2023-10-26 iso4217:USD shares iso4217:USD shares 0001430306 false 8-K 2023-10-26 TONIX PHARMACEUTICALS HOLDING CORP. NV 001-36019 26-1434750 26 Main Street Chatham NJ 07928 (862) 904-8182 false false false false Common Stock TNXP NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://tonixpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tnxp-20231026.xsd tnxp-20231026_lab.xml tnxp-20231026_pre.xml tnxp-8k_102623.htm http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tnxp-8k_102623.htm": { "nsprefix": "TNXP", "nsuri": "http://tonixpharma.com/20231026", "dts": { "schema": { "local": [ "tnxp-20231026.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "tnxp-20231026_lab.xml" ] }, "presentationLink": { "local": [ "tnxp-20231026_pre.xml" ] }, "inline": { "local": [ "tnxp-8k_102623.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://tonixpharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-10-26", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tnxp-8k_102623.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-10-26", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tnxp-8k_102623.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001839882-23-028167-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001839882-23-028167-xbrl.zip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end